• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Sensei Biotherapeutics Inc.

    6/3/26 4:52:58 PM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SNSE alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Sensei Biotherapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)




    81728A207

    (CUSIP Number)
    06/01/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    81728A207


    1Names of Reporting Persons

    ICS Opportunities II LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    41,561.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    41,561.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    41,561.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.1 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP Number(s):
    81728A207


    1Names of Reporting Persons

    Millennium Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    41,561.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    41,561.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    41,561.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.1 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP Number(s):
    81728A207


    1Names of Reporting Persons

    Millennium Group Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    41,561.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    41,561.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    41,561.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.1 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP Number(s):
    81728A207


    1Names of Reporting Persons

    Israel A. Englander
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    41,561.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    41,561.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    41,561.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.1 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Sensei Biotherapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    1405 Research Boulevard, Suite 125, Rockville, Maryland 20850
    Item 2. 
    (a)Name of person filing:

    ICS Opportunities II LLC Millennium Management LLC Millennium Group Management LLC Israel A. Englander
    (b)Address or principal business office or, if none, residence:

    ICS Opportunities II LLC c/o Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
    (c)Citizenship:

    ICS Opportunities II LLC - Cayman Islands Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    81728A207
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See response to Item 9 on each cover page.
    (b)Percent of class:

    See response to Item 11 on each cover page.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See response to Item 5 on each cover page.

     (ii) Shared power to vote or to direct the vote:

    See response to Item 6 on each cover page.

     (iii) Sole power to dispose or to direct the disposition of:

    See response to Item 7 on each cover page.

     (iv) Shared power to dispose or to direct the disposition of:

    See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit I
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    ICS Opportunities II LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:06/02/2026
     
    Millennium Management LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:06/02/2026
     
    Millennium Group Management LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:06/02/2026
     
    Israel A. Englander
     
    Signature:/s/ Israel A. Englander
    Name/Title:Israel A. Englander
    Date:06/02/2026

    Comments accompanying signature:  ** ICS OPPORTUNITIES II LLC By: Millennium Management LLC, its Investment Manager
    Exhibit Information

    Exhibit I: Joint Filing Agreement, dated as of June 2, 2026, by and among ICS Opportunities II LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

    Get the next $SNSE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNSE

    DatePrice TargetRatingAnalyst
    5/29/2026Overweight
    Cantor Fitzgerald
    5/22/2026$55.00Buy
    Citigroup
    4/20/2026$50.00Outperform
    Leerink Partners
    6/2/2025$5.00Buy
    H.C. Wainwright
    5/14/2024$5.00Overweight
    Stephens
    3/10/2022$12.00 → $10.00Overweight
    Piper Sandler
    7/1/2021$12.00Buy → Hold
    Berenberg
    6/29/2021$30.00 → $14.00Outperform → Perform
    Oppenheimer
    More analyst ratings

    $SNSE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Millennium Management Llc bought $141,364 worth of shares (4,215 units at $33.54) and sold $538,114 worth of shares (17,076 units at $31.51) (SEC Form 4)

    4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)

    5/15/26 4:24:06 PM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Millennium Management Llc bought $818,257 worth of shares (30,585 units at $26.75) and sold $89,390 worth of shares (3,250 units at $27.50) (SEC Form 4)

    4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)

    5/15/26 4:22:04 PM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNSE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Sensei Biotherapeutics

    Cantor Fitzgerald initiated coverage of Sensei Biotherapeutics with a rating of Overweight

    5/29/26 8:15:43 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Sensei Biotherapeutics with a new price target

    Citigroup initiated coverage of Sensei Biotherapeutics with a rating of Buy and set a new price target of $55.00

    5/22/26 8:50:05 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Sensei Biotherapeutics with a new price target

    Leerink Partners initiated coverage of Sensei Biotherapeutics with a rating of Outperform and set a new price target of $50.00

    4/20/26 8:28:17 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNSE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $SNSE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $SNSE
    SEC Filings

    View All

    Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

    First patient dosed in Phase 1b/2 trial of PIKTOR in HR+/HER2- advanced breast cancer Topline Phase 2 data in patients with advanced endometrial cancer expected in second half 2026 Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. "The first quarter of 2026 was transformational for the Company, with the acquisition of Faeth Therapeutics and the concurrent $200 million private placement in February, supported by a group of leading life sciences investors," said Christopher Gerry, President & General Counsel of Sensei Biotherapeutics. "This acquisition and injection of new capital will

    5/15/26 7:30:00 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    "Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies

    Issued on behalf of GT Biopharma, Inc. After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, and other historically immunotherapy-resistant solid tumors are suddenly among the busiest battlegrounds in oncology — and a new natural killer cell engager just joined the field SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- World Street Intelligence News Commentary — Until very recently, the immuno-oncology revolution had largely passed several of the most lethal solid tumor categories by. Checkpoint inhibitors, which transformed outcomes in melanoma, lung cancer, and renal cell carcinoma, have struggled to deliver meaningful benefit for the m

    5/14/26 10:55:00 AM ET
    $GTBP
    $ONCY
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer

    PIKTOR is an investigational all-oral, multi-node inhibitor targeting escape routes in the PI3K/AKT/mTOR pathway that single-node inhibitors leave open Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical-stage biotechnology company, announced today that the first patient was dosed in Study FTH-PIK-101 (NCT07558733), a Phase 1b/2 trial of PIKTOR in patients with HR+/HER2- advanced breast cancer. PIKTOR, an investigational, all-oral combination of serabelisib and sapanisertib, is designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway through PI3K-alpha and dual mTORC1/2 targeting, and became Sensei's lead program after the company acquired Faeth Therapeutics in February 2026.

    5/5/26 7:30:00 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Cambrian Biopharma Inc sold $500,543 worth of shares (25,000 units at $20.02), decreasing direct ownership by 16% to 130,142 units (SEC Form 4)

    4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)

    6/1/26 5:21:50 PM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Peyer James sold $500,543 worth of shares (25,000 units at $20.02), decreasing direct ownership by 16% to 130,142 units (SEC Form 4)

    4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)

    6/1/26 5:20:06 PM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Millennium Management Llc bought $141,364 worth of shares (4,215 units at $33.54) and sold $538,114 worth of shares (17,076 units at $31.51) (SEC Form 4)

    4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)

    5/15/26 4:24:06 PM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Sensei Biotherapeutics Inc.

    SCHEDULE 13G/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)

    6/3/26 4:52:58 PM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 10-K/A filed by Sensei Biotherapeutics Inc.

    10-K/A - Sensei Biotherapeutics, Inc. (0001829802) (Filer)

    6/2/26 9:01:24 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form S-3/A filed by Sensei Biotherapeutics Inc.

    S-3/A - Sensei Biotherapeutics, Inc. (0001829802) (Filer)

    6/2/26 8:56:26 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNSE
    Leadership Updates

    Live Leadership Updates

    View All

    Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

    - SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 - - Cash runway extended into the second quarter of 2026 - BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter ended September 30, 2024, and provided corporate updates. "The third quarter of 2024 saw significant progress in advancing patient enro

    11/14/24 7:30:00 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

    - Promising Phase 1/2 SNS-101 clinical data presented at ASCO 2024 - - Enrollment in the Phase 1 dose expansion of SNS-101 clinical trial advancing with initial data on track for Q4 2024 - - Strong balance sheet with cash runway into the fourth quarter of 2025 - BOSTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the second quarter ended June 30, 2024, and provided corporate updates. "Collectively, the clinical data presented on SNS-101 over the past six month

    8/6/24 7:30:00 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

    - Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limiting toxicities - - Company to present topline clinical data from the SNS-101 Phase 1 dose escalation study at the 2024 ASCO Annual Meeting - - Enrollment in the dose expansion portion of the clinical study advancing - - Strong balance sheet with cash runway into fourth quarter of 2025 - BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter ended March 31, 2024, and provide

    5/9/24 7:30:00 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNSE
    Financials

    Live finance-specific insights

    View All

    "Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies

    Issued on behalf of GT Biopharma, Inc. After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, and other historically immunotherapy-resistant solid tumors are suddenly among the busiest battlegrounds in oncology — and a new natural killer cell engager just joined the field SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- World Street Intelligence News Commentary — Until very recently, the immuno-oncology revolution had largely passed several of the most lethal solid tumor categories by. Checkpoint inhibitors, which transformed outcomes in melanoma, lung cancer, and renal cell carcinoma, have struggled to deliver meaningful benefit for the m

    5/14/26 10:55:00 AM ET
    $GTBP
    $ONCY
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement

    Acquisition of Faeth and concurrent $200 million private investment positions the combined company to advance its pipeline across key clinical milestones in endometrial and breast cancer PIKTOR is an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway in development across solid tumor settings, including endometrial and breast cancer Sensei to host an audio-only conference call and webcast today, February 18, 2026, at 8:30 a.m. ET Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) today announced that it has acquired Faeth Therapeutics Inc. ("Faeth"), a clinical-stage biotechnology company developing multi-node therapies that target tumor metabolism and signaling. The

    2/18/26 8:00:00 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sensei Biotherapeutics Adopts Stockholder Rights Agreement

    BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today announced that a special committee of the Board of Directors adopted a limited duration stockholder rights agreement (the "Rights Agreement") to protect stockholder interests and maximize value for all stockholders. The Rights Agreement is intended to reduce the likelihood that any entity, person or group is able to gain control of Sensei through open market accumulation without paying all stockholders an appropriate control premium or providing the Board sufficient opportunity to make i

    3/7/23 5:15:00 PM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNSE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Sensei Biotherapeutics Inc. (Amendment)

    SC 13D/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)

    3/7/24 6:00:48 PM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Sensei Biotherapeutics Inc. (Amendment)

    SC 13D/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)

    2/13/24 5:34:37 PM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Sensei Biotherapeutics Inc.

    SC 13D - Sensei Biotherapeutics, Inc. (0001829802) (Subject)

    11/3/23 5:03:47 PM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care